Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Alumis completes patient enrollment for phase 2b study of lupus drug

Alumis has completed patient enrollment for its global phase 2b LUMUS study evaluating the lupus drug ESK-001 and expects topline data in the third quarter of 2026. The company also announced the completion of its merger with ACELYRIN, Inc. to strengthen its financial position, as well as a management promotion. Analysts view Alumis's progress and pipeline positively, despite ongoing financial challenges. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Alumina has already paid €0.0668 in dividends. The last payout was in September 2022.

Financials

In the last year, Alumina had revenue of €650.12k and net profit of -€139.35m

(EUR)	2023	YoY
Revenue	650.12k	11.20%
Gross profit	308.11k	30.62%
Net profit	-139.35m	246.42%
EBITDA	223.11m	34.59%

Fundamentals

Metric	Value
Market capitalization	€2.62bn
Number of shares	2.9bn
52-week high/low	€1.19 - €0.43
Dividends	No
Beta	1.25
P/E ratio	-18.61
PEG ratio	-0.19
P/B ratio	2.00
P/S ratio	3,988.09

Company profile

Alumina Limited, through its 40% interest in Alcoa World Alumina and Chemicals, engages in bauxite mining, alumina refining, and aluminum smelting businesses. The company has a network of bauxite mines and alumina refineries in Australia, Guinea, Brazil, Spain, and Saudi Arabia; and holds a 55% interest in the Portland aluminum smelter in Victoria, Australia. It is also involved in shipping operations. The company was formerly known as WMC Limited and changed its name to Alumina Limited in December 2002. Alumina Limited was incorporated in 1970 and is headquartered in Southbank, Australia.